Clicky

PaxMedica, Inc.(PXMD)

Description: PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.


Keywords: Medicine Disorders Chronic Condition Drug Therapies Autism Spectrum Disorder Chronic Fatigue Syndrome Myelitis

Home Page: www.paxmedica.com

PXMD Technical Analysis

303 South Broadway
Tarrytown, NY 10591
United States
Phone: 914-987-2876


Officers

Name Title
Mr. Michael L. Derby M.B.A., M.S. Exec. Chairman
Mr. Howard J. Weisman CEO & Director
Mr. Stephen Douglas Sheldon Chief Financial Officer
Mr. Zachary Rome COO & Director
Dr. Stefan K. F. Schwabe M.D., Ph.D. Chief Medical Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 15.2107
Price-to-Book MRQ: 10.4824
Price-to-Sales TTM: 0
IPO Date: 2022-08-26
Fiscal Year End: December
Full Time Employees: 2
Back to stocks